Variable and conserved neutralization antigens of human immunodeficiency virus.
about
Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causationPathogenesis of human immunodeficiency virus infectionTwo orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infectionHIV-1 neutralizing antibodies: understanding nature's pathwaysCharacterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120Retroviruses and human disease.Rapid evolution of the neutralizing antibody response to HIV type 1 infectionGetting to know HIV.Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysCoexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controllerImmunological studies of the basis for the apathogenicity of simian immunodeficiency virus from African green monkeysDiscontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoproteinAntibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical TriaInduction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display.Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.The development of an AIDS vaccine: progress and promise.Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processingPresence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionVaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants.Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
P2860
Q24564855-9F31D799-BD66-4CDC-8B1C-21A76A2317C8Q24627627-9429AC23-0404-4441-9389-AF00114DF12FQ24634681-DA2B7498-0C4A-4E46-A6B3-A562F4D0E1C0Q24652969-7461C4CF-B432-4F44-9AA4-B45DE202A005Q27000480-6E71E977-BDAA-4990-9CB9-21344DE04804Q28646835-1F10D022-57BC-4748-AD78-C3EBFC840803Q28769657-FAA766B5-DFDB-479A-A9E8-F53F73AFD8DAQ29618603-E5732C36-7926-4985-AB28-14F1E53C6C4DQ30327142-9B4C8995-A9B1-4A71-AF9A-7A11AF4557F5Q33560772-34067930-4978-4348-9209-C2E7E5F88F03Q33567984-D6A29218-74A2-4064-A876-57268521A959Q33632668-AC9E02E4-6339-425E-AD2F-6CED79A16526Q33671780-2EB8F507-279F-4274-A710-84B6D6481D7AQ33784708-C5D279B9-01F7-427C-9A85-0E4AD15CB2FDQ33785114-EBA4A008-55BC-4154-B005-55849918A74EQ33786447-5AEBD7BE-B4A6-4835-8CF2-3329BCF7C18CQ33903860-0BD4C8F7-A6FD-45BD-B759-3BD34D7ADEF1Q33937274-5927D6BB-8E29-4FFB-AF11-8BAE4B5A291FQ34047226-C1C19D7D-73DF-43A0-BABD-FEBBE5E00910Q34150125-DDEB5237-EEFB-4E09-8738-53FC1A187916Q34171212-66F6C084-F9D6-442D-8BDB-046E4F3E73C5Q34171623-7B2FFD23-92AA-4F37-A2F7-58E9319ABDB5Q34301897-D30FA85A-D0B3-434B-97EB-8583F2D15E7CQ34335264-0C9D61D6-9194-43F2-8CA1-F296BB2879F6Q34373003-D2B08608-C1DB-4B4E-83D9-CDE57876D43EQ34376844-C0E91A28-FFC3-4BE0-BE1D-D974B3671121Q34397758-FD729C96-D7E2-4D77-A0C2-9847F037CA31Q34640420-49925A5B-4995-4920-B71B-5AD7B7AAC49EQ34675856-B97F98FD-4562-4F2B-813F-AFEB07DBA03FQ35113855-52DAF0A4-77A6-43D6-85AA-899BFEE2E325Q35122914-3B096BCF-9CB3-44E4-8200-76D2A41FAE32Q35224610-C59FA1A5-4C30-4C5C-8E59-77E5E010E94DQ35848078-8404DFBE-C4E4-436E-9DFE-19BF71D26D4EQ35849408-1CF6465F-2456-4090-8AEE-23C35241673BQ35853750-DB15ADBC-31E8-4128-8987-B67391A77BADQ35879871-BCDD0FC8-B175-4771-B28F-E815033DC16EQ36230737-8ED06777-4ED4-4CCE-BA3D-A60C7C078AB8Q36246646-A2BCE18E-64CD-4328-BFA3-E12373FFCCC6Q36353458-822DE0D2-B782-4A5D-B72E-003B1358A445Q36365085-DF628129-E292-4AF7-A6E4-598E1FF65F17
P2860
Variable and conserved neutralization antigens of human immunodeficiency virus.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Variable and conserved neutralization antigens of human immunodeficiency virus.
@en
type
label
Variable and conserved neutralization antigens of human immunodeficiency virus.
@en
prefLabel
Variable and conserved neutralization antigens of human immunodeficiency virus.
@en
P2093
P356
P1433
P1476
Variable and conserved neutralization antigens of human immunodeficiency virus.
@en
P2093
P2888
P304
P356
10.1038/324572A0
P407
P577
1986-12-01T00:00:00Z
P6179
1037493730